CSL Seqirus
General Information
Identification Code: 235418549954-90
Website: [object Object]
Entity Form: Plc
Registration Category: Companies & groups
Registration Date: 4/24/2023
Last Update: 4/13/2024
EP Accredited Number: 1
Mission & Interests
Goals: At CSL Seqirus we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. CSL Seqirus is one of the largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccine subsidiary, BioCSL.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Business and industry
- Public health
- Research and innovation
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: EU Health Data Space
EU Health Emergency Response Authority
EU Pharmaceutical legislation
EU Emergency Authorisation Regulation
ECDC and EMA
Communication Activities: As members of the trade association Vaccines Europe, we have conducted an EU Flu Day campaign in 2020, 2021, 2022 and in 2023.
In 2023 we sponsored an event at the European Parliament, hosted by MEP Stelios Kympouropoulos, on Real World Evidence for healthcare policymaking.
CSL Seqirus also makes grants to the European Scientific Working group on Influenza (ESWI) to support influenza scientific exchange and education and young scientist awards.
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: CSL SeqirusLevel 3, 8AA, 29 Market St
Post Code: SL6 8AD
City: Maidenhead
Country: UNITED KINGDOM
Phone: [object Object]
EU Office
Address: CSL SeqirusLevel 3, 8AA, 29 Market St
Post Code: SL6 8AD
City: Maidenhead
Country: UNITED KINGDOM
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: N/A
Membership Information
Members10 Percent: 1
Members25 Percent: 2
Members50 Percent: 1
Members75 Percent: 0
Members: 4
Members F T E: 1.100000023841858
Info Members: N/A
Structure
Structure Type: Structure
Is Member Of: N/A
Organisation Members: Vaccines Europe